<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874859</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0051</org_study_id>
    <nct_id>NCT02874859</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema</brief_title>
  <acronym>MODEVA</acronym>
  <official_title>Aflibercept Injection for Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a non-interventional retrospective study on the efficiency and the tolerance of&#xD;
      intravitreal injections of Aflibercept on vitrectomized eyes in the diabetic macular oedema&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema (DME) is the leading cause of blindness among people of working age.&#xD;
      Treatment of DME included blood pressure and glycemic control, grid laser, intravitreal&#xD;
      injection of steroids (acetonide of triamcinolone, dexamethasone implant, fluocinolone&#xD;
      implant) or anti-Vascular endothelial growth factor (VEGF) therapy (Bevacizumab, Ranibizumab,&#xD;
      Aflibercept) (2015). The advent of anti-VEGF therapy has revolutionized the management of&#xD;
      DME. Aflibercept, one of the drugs in this group has recently been approved in France.&#xD;
      However, there is no report in the efficacy and tolerance of Aflibercept in vitrectomized&#xD;
      eyes in the diabetic macular oedema . In this study, in order to prove the efficiency and&#xD;
      tolerance of Aflibercept, data will be collected in a anonymous way in medical records of&#xD;
      patients having received a treatment by Aflibercept in the past.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Actual">August 19, 2020</completion_date>
  <primary_completion_date type="Actual">August 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Estimation of visual acuity after 96 weeks of treatment with Aflibercept</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of the central macular thickness</measure>
    <time_frame>96 weeks</time_frame>
    <description>Describe the evolution of the Central macular thickness during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of number of Aflibercept injections received</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic vitrectomised patients with macular edema, treated with Aflibercept in the past&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients aged between 19 and 90 years old&#xD;
&#xD;
          -  Patients with the following characteristics at the beginning of the Aflibercept&#xD;
             therapy :&#xD;
&#xD;
        HbA1c &lt; 9% Diabetic macular oedema with the central affected Visual acuity between 1/20 and&#xD;
        5/40 (between 20 and 70 letters ETRS) Patients who had a vitrectomy over 3 months ago&#xD;
&#xD;
          -  Patients who did not received an anti-VEGF treatment or any other treatment for their&#xD;
             diabetic macular edema 3 months before the beginning of the injections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refused the collection of their data in medical records&#xD;
&#xD;
          -  Patients with a macular ischemia of more than 1500µm diagnosed via an avascular&#xD;
             central fluorescein angiography before the inclusion&#xD;
&#xD;
          -  Patients with a recent cardiovascular incident (heart attack, stroke dating for less&#xD;
             than 3 months before the inclusion)&#xD;
&#xD;
          -  Pregnancy at the moment of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thi Ha Chau TRAN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupement des Hôpitaux de l'Institut Catholique de Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pr MILAZZO Solange</name>
      <address>
        <city>Amiens</city>
        <state>Hauts De France</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tran Thi Ha Chau</name>
      <address>
        <city>Lomme</city>
        <state>Hauts De France</state>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bénédicte DUPAS</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stéphanie BAILLIF</name>
      <address>
        <city>Nice</city>
        <state>Paca</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr DOMINGUEZ</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pr KODJIKIAN</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Franck BECQUET</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr UZZAN</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DIABETIC RETINOPATHY</keyword>
  <keyword>Intravitreal aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

